For patients diagnosed with Crohn’s disease (CD), there seems to be an opportune window in which early intervention may improve outcomes of the disease. Dr. Edward Loftus explains details of a multicenter collaborative study which found that patients with CD, for 2 years or less, are more likely to achieve a complete response to vedolizumab (Entyvio), than patients with longer disease duration.
Researchers considered several factors to evaluate the relation between disease duration and vedolizumab effectiveness –
What are the implications for patient care?
The findings of the study suggest that patients who’ve been diagnosed with Crohn’s disease should begin treatment with an anti-TNF agent or vedolizumab as soon as possible.
Meet other people, talking about Crohn’s disease, on Mayo Clinic Connect – join the conversation, share experiences, ask questions, and discover your support network. Here are some discussions you might like to follow...